Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis

Kyoko Tomita, Rohit Kohli, Brittany L. MacLaurin, Petra Hirsova, Qianqian Guo, Luz H.Gutierrez Sanchez, Harris A. Gelbard, Burns C. Blaxall, Samar H. Ibrahim

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

With the increase in obesity worldwide, its associated comorbidities, including nonalcoholic steatohepatitis (NASH), have become a public health problem that still lacks effective therapy. We have previously reported that mixed-lineage kinase 3-deficient (MLK3-deficient) mice are protected against diet-induced NASH. Given the critical need to identify new therapeutic agents, we sought to examine whether the small-molecule MLK3 inhibitor URMC099 would be effective in reversing diet-induced murine NASH. C57BL/6J mice were fed either a diet high in saturated fat, fructose, and cholesterol (FFC), or a chow diet for 24 weeks. Mice were treated with either URMC099 (10 mg/kg) twice daily by intraperitoneal injection or its vehicle during the last 2 weeks of the feeding study. FFC-fed mice receiving URMC099 had similar body weight, caloric intake, homeostatic model assessment of insulin resistance, metabolic phenotype, and hepatic steatosis compared with vehicle-treated mice. Furthermore, FFC-fed mice treated with URMC099 had less hepatic macrophage infiltration, activation, and proinflammatory polarization, as well as less liver injury and fibrosis when compared with vehicle-treated mice. In conclusion, URMC099 is well tolerated in mice without obvious toxicities and appears to be efficacious in reversing diet-induced NASH. Hence, URMC099 may serve as a therapeutic agent in human NASH.

Original languageEnglish (US)
JournalJCI Insight
Volume2
Issue number15
DOIs
StatePublished - Aug 3 2017

Keywords

  • Hepatology

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis'. Together they form a unique fingerprint.

  • Cite this

    Tomita, K., Kohli, R., MacLaurin, B. L., Hirsova, P., Guo, Q., Sanchez, L. H. G., Gelbard, H. A., Blaxall, B. C., & Ibrahim, S. H. (2017). Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis. JCI Insight, 2(15). https://doi.org/10.1172/jci.insight.94488